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Background /

Clinical Presentation and Epidemiology of Hypoglycemia
■ ■ Hypoglycemia is a common adverse effect of treatment for diabetes mellitus, resulting in significant short-term and long-term morbidity and affecting both physical (cognitive and neurological impairments, hypothermia, palpitations, coma) and psychological (quality of life, patient functioning, fear) outcomes. Severe hypoglycemia is characterized by coma or convulsions and can precipitate hemiparesis or stroke, and can be fatal. 3 Treatment by a caregiver or health professional is required, and typically involves the administration of glucagon to increase blood glucose levels. 2 ■ ■ Patients with Type I diabetes mellitus (T1DM) are particularly at increased risk of hypoglycemia; among patients with Type II diabetes mellitus (T2DM), insulin-dependent patients and/or those using sulfonylureas are at a heightened risk.
1 ■ ■ Risk factors for severe hypoglycemia include duration of T1DM, duration of insulin therapy in T2DM, younger ages (i.e., pediatric), older ages (i.e., elderly), strict glycemic control, and renal impairment.
1
Glucagon Kits
■ ■ The American Diabetes Association recommends that all patients with diabetes at a heightened risk of hypoglycemia be prescribed glucagon kits for administration by a caregiver or those in close contact with the patient.
2 ■ ■ Despite the availability and benefits of glucagon kits, these may be underutilized. [4] [5] [6] Furthermore, currently available rescue kits require reconstitution of the glucagon powder, thus requiring that close contacts are adequately trained on administering the product. 2. The probability of an ambulance call for patients with no kit is equivalent to the probability of transport for patients who were unsuccessfully administered a glucagon product 3. The probability of transport for patients with no kit is equivalent to the probability of transport for patients who were unsuccessfully administered a glucagon rescue product 4. The probability of a non-ambulance trip to the ED for patients with no kit is equivalent to the probability for a similar trip among patients who were unsuccessfully administered a glucagon rescue product Results / Under the base case scenario, the average costs of a severe hypoglycemic event assuming successful use and unsuccessful use of glucagon rescue are equal to $1,709 and $2,827, respectively. Costs related to ambulance use, emergency room use and hospital admission are listed in Table 4 .
Assuming a base case successful use rate of 40%, the value of a glucagon rescue product would be equal to $151.52 in T1DM and $47.70 in T2DM. Increasing the hypothetical successful use rate of glucagon to 60% increases the value to $227.28 and $71.56, respectively. The value of increasing the successful use rate was higher for T1DM patients than for T2DM across all ranges of successful use values, which was driven by a higher incidence rate of SHE in this population (Figure 2 ). We estimated that for every 10 percent increase in successful use, the value of a glucagon rescue product would increase by $38 and $12 for T1DM and T2DM, respectively.
Sensitivity Analysis
Sensitivity analyses around inputs for the T1DM population are shown in Figure 3 . Results from sensitivity analyses around parameters for the T2DM population were similar to those for the T1DM population (results not shown).
Analyses demonstrated that the model was most sensitive to the probability of ER use and ambulance transport among successful and unsuccessful users, and the prevalence of severe hypoglycemic events.
Implications /
■ ■ This analysis demonstrates the potential value that increasing successful use of glucagon rescue medication has in reducing potential downstream health resource utilization and associated costs.
■ ■ The most value from improved glucagon rescue medication use can be derived in the T1DM population, where an increased risk of severe hypoglycemia exists, though downstream savings in the T2DM population may also be possible.
■ ■ Though new technologies may offer an increase in convenience, they also offer reduction of downstream healthcare costs to payers, a subject worthy of greater study.
Limitations / ■ ■ Limited data exist around the unsuccessful use of glucagon rescue medication. Furthermore, the clinical implications of delayed glucagon rescue medication from the lack of availability or improper administration of glucagon have not been well-studied.
■ ■ Limited data exist around key types of healthcare utilization (i.e., ambulance use, ER visits, inpatient visits) according to the successful use of glucagon rescue.
■ ■ As this analysis was conducted from a U.S. healthcare payer perspective, indirect costs were not included in the model. Increasing successful use of glucagon rescue kits can have a significant impact not only on costs related to healthcare utilization, but also on mortality. Conducting this analysis from a societal perspective can further help demonstrate the value of glucagon rescue kits to policymakers and other stakeholders. 
